Log2 fold change (FC), mean and standard deviation (SD) of each lipid specie from the simple steatosis (SS) and metabolic dysfunction-associated steatohepatitis (MASH) groups, and... by Laia Bertran (3685147)

Expression of Caspase-3 in HCT 116 and Hep 3B: <i>2A. and 2B.</i> by Vidya G. Bettada (22208808)

Treatment with vitamin D3 reduced the viability of cancer cell lines: <i>1A & 1B.</i> by Vidya G. Bettada (22208808)

“…Human and rat glioblastoma cell lines U-87 MG and C6, respectively; which were exposed to vitamin D3 demonstrated a statistically significant reduction in viable cells with increasing time and treatment concentration. 1H. …”

Vitamin D3, but not the Cisplatin, could moderately reduce STZ-induced hyperglycemia in mice (a) Schematic representation of experimental protocol followed in the study: After accl... by Vidya G. Bettada (22208808)

“…The data showed a significant increase in fasting blood glucose (FBG) beginning from day 6. …”

Receiver operating characteristic curve analyses for the prediction of hepatitis C. by Lu Han (151620)

Subjects:

Exploring the correlation between systemic inflammation biomarkers and HCV infection (logarithm base 2). by Lu Han (151620)

Subjects:

Threshold effect analysis of systemic inflammatory biomarkers on hepatitis C using two-piece wise linear regression. by Lu Han (151620)

Subjects:

Exclusion and enrollment summary from NHANES. by Lu Han (151620)

Subjects:

Demographic information and baseline population characteristics. by Lu Han (151620)

Subjects:

Stratified associations between systemic inflammation biomarkers and hepatitis C (OR 95%, <i>P</i> value, LOG base 2). by Lu Han (151620)

Subjects:

General addictive models demonstrate the relationship between systemic inflammatory biomarkers and anti-HCV. by Lu Han (151620)

Subjects:

Comparison of systemic inflammation biomarkers in infected and uninfected populations. by Lu Han (151620)

Subjects:

Joinpoint regression trends in crude hospitalization and mortality rates of HPV-associated cancers in Mexico (2011–2019). by Juan Carlos Orengo (21546581)

Subjects:

Distribution of HPV-associated and attributable cancer deaths by type and sex, Mexico, 2011-2019. by Juan Carlos Orengo (21546581)

Subjects:

Hospitalizations for HPV-associated and HPV-attributable cancers by type and sex in Mexico (2011-2019): total numbers, averages, and crude rates per 100,000 population. by Juan Carlos Orengo (21546581)

Subjects:

Trends in age-standardized hospitalization rates by HPV-associated cancer type and sex (2011–2019): annual percentage change and average annual percentage change. by Juan Carlos Orengo (21546581)

Subjects:

Mortality for HPV-associated and HPV-attributable cancers by type and sex in Mexico (2011-2019): total numbers, averages, and crude rates per 100,000 population. by Juan Carlos Orengo (21546581)

Subjects:

Joinpoint regression trends in age-standardized hospitalization and mortality rates of HPV-associated cancers in Mexico (2011-2019). by Juan Carlos Orengo (21546581)

Subjects:

Trends in age-standardized mortality rates by HPV-associated cancer type and sex (2011–2019): annual percentage change and average annual percentage change. by Juan Carlos Orengo (21546581)

Subjects:

Distribution of HPV-associated and attributable cancer hospitalizations by type and sex, Mexico, 2011-2019. by Juan Carlos Orengo (21546581)

Subjects: